NCT03806790 - Efficacy and Safety of LEO 90100 Foam in Japanese Subjects With Psoriasis Vulgaris | Biotech Hunter

Enrollment

182

Participants

Timeline

Start Date

January 24, 2019

Primary Completion Date

June 10, 2019

Study Completion Date

June 10, 2019

Conditions

Psoriasis Vulgaris

Interventions

DRUG

LEO 90100 foam

Once daily topical application of foam from a can to psoriasis lesions. Dose depends on size of lesion.

DRUG

Dovobet® ointment

Once daily topical application of ointment from a tube to psoriasis lesions. Dose depends on size of lesion.

Trial Locations (16)

811-3217

Leo Pharma Investigational Site, Fukutsu

080-0013

Leo Pharma Investigational Site, Obihiro

004-0063

Leo Pharma Investigational Site, Sapporo

006-0814

Leo Pharma Investigational Site, Sapporo

060-0807

Leo Pharma Investigational Site, Sapporo

921-8801

Leo Pharma Investigational Site, Nonoichi

213-0001

Leo Pharma Investigational Site, Kawasaki

220-6208

Leo Pharma Investigational Site, Yokohama

981-3133

Leo Pharma Investigational Site, Sendai

330-0854

Leo Pharma Investigational Site, Saitama-shi

173-8605

Leo Pharma Investigational Site, Itabashi-ku

115-0045

Leo Pharma Investigational Site, Kita-ku

136-0074

Leo Pharma Investigational Site, Koto-Ku

108-0014

Leo Pharma Investigational Site, Minato-Ku

158-0094

Leo Pharma Investigational Site, Setagaya City

158-0097

Leo Pharma Investigational Site, Setagaya City